Pfizer, Astellas win FDA priority review for Padcev in bladder cancer with Merck's Keytruda
Source: SeekingAlpha
2026-04-20 07:20:14 ET
More on Pfizer, Merck, etc.
- Pfizer: Painful Recovery Underway
- Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
- Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare - Slideshow
- Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP
- Merck gains after six-day losing streak
Read the full article on Seeking Alpha
For further details see:
Pfizer, Astellas win FDA priority review for Padcev in bladder cancer with Merck’s Keytruda
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.42% G/L:
$13.39 Last:
82,071 Volume:
$13.4984 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
